Parallel Bio develops tools that help in the discovery and development of immunotherapies, to eliminate current barriers and create the fastest path to a drug that works. Parallel Bio's platform combines best-in-class human immune organoids with computational methods to generate unprecedented insights into human health and disease.
Zymochem provides a carbon-efficient bio-manufacturing platform that converts renewable feedstocks into bio-based materials without compromising price, performance, scale, or sustainability while minimizing CO2 loss during production. It also accelerates a real-zero economy by relieving carbon emissions in product development, use, and end-of-life.
Modern Meadow is a pioneer in sustainable materials, creating innovative biomaterials like BIO-VERA® that replace petrochemical and animal-derived inputs. Their technology platform allows seamless integration into existing manufacturing processes, enabling industries such as fashion, footwear, and automotive to produce high-quality, sustainable products. With over 250,000 handbags and jackets produced and 11 global partners, Modern Meadow is positioned as a leader in bioinnovation, driving sustainability and performance in material production.
Appia Bio is a biotechnology company that focuses on the research and development of off-the-shelf allogeneic cell therapies. It works on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).
CytoVale is a medical technology company that focuses on advancing early detection technologies to diagnose immune-mediated diseases, revolutionizing diagnostics using cell mechanics and machine learning. The company was founded in 2013 by Ajay Shah and Dino Di Carlo and is based in San Francisco, California.
CellChorus provides a comprehensive, dynamic analysis of single cells for biopharmaceutical companies. The company’s TIMING™ platform applies visual AI to evaluate cell activation, killing and movement as a function of time in order to maximize our understanding of the cellular function, state, and phenotype of immuno-oncology and other therapies.